Back

Aardvark Therapeutics faces securities lawsuit after shares plunge 56%

Verifying
  • Hagens Berman notified Aardvark investors of a pending securities class action.
  • 56%: Aardvark shares fell after the company paused its Phase 3 HERO trial.
  • October 13, 2026: Investors must submit lead plaintiff motions by this deadline.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.